Search

Displaying all 2 results
DrugBest match

Siponimod

go.drugbank.com/drugs/DB12371
ApprovedInvestigational

Siponimod, also known as Mayzent, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a sphingosine-1-phosphate (S1P) receptor modulator and is thought to play a role in su...

  1. Indication

    Relapsing Multiple Sclerosis (RMS)

    go.drugbank.com/conditions/DBCOND0044896
    Drugs: Cladribine · Daclizumab · Fingolimod · Interferon beta-1a · Interferon beta-1b · Ocrelizumab +5 more